Key Takeaways
- AOD9604 is a modified C-terminal fragment of human growth hormone, not full recombinant HGH.
- Analytical literature defines AOD9604 as hGH residues 177–191 with an additional N-terminal tyrosine; commercial use of “HGH fragment 176–191” is not always chemically precise.
- Early rat and mouse studies measured fat oxidation, lipolysis, energy balance, hGH-receptor activity, and beta-3 adrenergic signalling.
- The animal findings did not translate into conclusive human weight-loss efficacy: FDA’s 2024 review says a 24-week Phase 2B study failed its commercial efficacy objective.
- FDA states that AOD9604 free base and AOD9604 acetate are not components of an FDA-approved drug and identified unresolved safety and evidence gaps for proposed compounding uses.
- BioPharma AOD9604 5mg is laboratory research material only, not a human or veterinary product.
AOD9604 research began with a narrow question: could a modified fragment of human growth hormone reproduce selected fat-metabolism effects without reproducing the full hormone’s receptor activity? Rodent studies reported changes in fat oxidation, lipolysis, body-weight gain, and beta-3 adrenergic receptor expression. However, the available human development record did not establish a successful obesity treatment. A 2024 FDA evaluation reports that the major Phase 2B program failed to produce the weight-loss result needed for commercial development.
Research boundary: This evidence review is for scientific education only. BioPharma compounds are for laboratory and research use only, not for human or veterinary use. Nothing below provides dosing, route, administration, treatment, efficacy, or safety guidance.
What Is AOD9604?
AOD9604 is a synthetic peptide derived from the C-terminal region of human growth hormone, or hGH. Exact sequence language matters. A 2015 analytical study defines AOD9604 as hGH amino acids 177–191 with an additional tyrosine at the N-terminus. That makes it a modified 16-residue peptide. The same paper developed a urine-detection method and identified candidate metabolites after incubation in serum and urine.
Retail descriptions frequently call the compound “HGH fragment 176–191.” That phrase is useful as a search alias, but it should not replace sequence verification. A peptide described only by a nickname may refer to a related fragment without proving identity, purity, counter-ion, or modification state. Researchers should pair a catalog name with lot-specific analytical documentation rather than assuming two labels are interchangeable.
Why was the C-terminal region studied?
Early investigators explored whether a smaller hGH-derived structure could retain selected metabolic observations while avoiding the full hormone’s growth-hormone-receptor activity. That hypothesis produced a series of rodent studies around 2000–2001. It did not establish that every hGH effect resides in the fragment or that animal outcomes would translate to people.
What Did Early AOD9604 Studies Measure?
Metabolic observations in obese rats
A 2000 study in obese Zucker rats reported lower body-weight gain and increased lipolytic activity after repeated experimental exposure. The investigators also reported no adverse change in insulin sensitivity under their study conditions. These were animal-model observations with a specific design; they are not evidence of a safe or effective human-use protocol.
Fat oxidation and hGH-receptor testing in mice
A 2001 mouse study compared intact hGH with AOD9604 in obese and lean animals. In obese mice, both compounds were associated with reduced weight gain, greater fat oxidation, and higher plasma glycerol. Unlike intact hGH, AOD9604 did not compete for the hGH receptor or induce proliferation in an hGH-receptor-dependent cell assay. That finding supports a mechanistic difference from full hGH, but it does not prove the absence of all growth-related or off-target effects.
Beta-3 adrenergic receptor research
A second 2001 study examined beta-3 adrenergic receptor involvement. Chronic exposure increased beta-3 receptor RNA expression in obese mice, while knockout experiments showed that the observed long-term weight and lipolysis changes depended on the presence of that receptor system. The authors also found an acute energy-expenditure observation in knockout mice, leading them to conclude that AOD9604’s actions were not mediated directly through the receptor even though receptor expression could contribute to lipolytic sensitivity.
This distinction is important: the published foundational studies emphasize fat oxidation, hGH-receptor independence, and beta-3 adrenergic biology. They do not establish AMPK activation as the settled primary mechanism for AOD9604. Mechanism summaries should follow what the cited experiments actually measured.
How Does AOD9604 Compare with Full Recombinant HGH?
| Research feature | AOD9604 | Full recombinant hGH |
|---|---|---|
| Structure | Modified C-terminal fragment; residues 177–191 plus an added N-terminal tyrosine in the analytical literature | Full 191-amino-acid human growth hormone protein |
| hGH-receptor assay | Did not compete for the hGH receptor or induce receptor-dependent cell proliferation in a cited preclinical study | Binds and activates the growth hormone receptor |
| Foundational model | Primarily obese rat and mouse metabolism experiments | Extensive physiological, pharmaceutical, and indication-specific research |
| Human development result | Obesity program discontinued after unsuccessful Phase 2B efficacy outcome | FDA-approved products exist for specific indications |
| Regulatory status | Not a component of an FDA-approved drug | Approved products have indication-specific labels and controls |
The comparison does not make the materials substitutes. A short fragment has different analytical, pharmacokinetic, receptor, and evidence questions from the parent hormone. Researchers comparing catalog materials can also review BioPharma’s HGH Frag 176–191 listing; the separate listing is a reason to verify exact identity rather than infer equivalence from a nickname.
What Happened in Human Development?
Early clinical development existed, but the public record is incomplete
A 2004 development summary reported that AOD9604 had entered Phase II research. Later reviews described it as a human growth-hormone fragment in clinical development. The most detailed public reconstruction now comes from FDA’s November 2024 briefing document for the Pharmacy Compounding Advisory Committee.
The Phase 2B OPTIONS study did not establish commercial efficacy
According to FDA’s review, the OPTIONS study enrolled 536 adults with obesity and randomized 502 participants. It was described as a 24-week, randomized, double-blind, placebo-controlled study with three oral AOD9604 groups plus diet and exercise support. FDA reports that the overall population did not respond consistently and that the observed differences were too small to reach statistical significance. Metabolic Pharmaceuticals announced in February 2007 that the results did not support commercial viability for obesity and terminated development for that condition.
FDA also noted that it could not locate a full publication of the study methods and results and did not find AOD9604 studies listed on ClinicalTrials.gov. That means the company and regulatory records are useful for trial history, but they do not provide the transparency of a complete peer-reviewed report and registry record.
What Does FDA’s Review Say About Regulatory Status?
The 2024 FDA briefing evaluated AOD9604 free base and AOD9604 acetate for possible inclusion on the federal 503A bulk drug substances list. FDA stated that neither substance is a component of an FDA-approved drug and concluded that the evidence criteria weighed against list inclusion. The review identified limited clinical safety information, no pharmacokinetic or bioavailability information for the proposed routes, and unresolved concerns about impurities, aggregation, immunogenicity, and human safety.
Why “GRAS” is not the same as drug approval
Online summaries sometimes say AOD9604 “received FDA GRAS approval.” That wording is misleading. GRAS is a food-law concept, not an approval of a drug for treatment, and FDA’s 2024 document records a private “USA GRAS Status” claim supplied in nomination materials rather than identifying AOD9604 as an approved medicine. The defensible regulatory statement is narrower: AOD9604 is not a component of an FDA-approved drug, and a food-ingredient safety position cannot be used as proof of therapeutic approval, injectable safety, or clinical efficacy.
Evidence Quality and Research Gaps
| Evidence layer | What it contributes | What remains unresolved |
|---|---|---|
| Rodent metabolism studies | Hypotheses about fat oxidation, lipolysis, hGH-receptor independence, and beta-3 adrenergic biology | Human translation, long-term safety, and reproducibility across models |
| Analytical metabolism study | Sequence definition, urine detection, and candidate in-vitro metabolites | Clinical pharmacokinetics and bioavailability |
| Company Phase 2B record | Evidence that a substantial controlled obesity study occurred | Full peer-reviewed methods, complete results, and registry transparency |
| FDA 2024 evaluation | Current regulatory assessment of identity, evidence, effectiveness, and safety concerns | It is a compounding-list evaluation, not an approved-product review |
The evidence base therefore supports an evidence-aware research question, not a benefit promise. The foundational mechanistic work is preclinical, the major human efficacy program was unsuccessful, and the regulatory review documents significant gaps. Those limits should remain beside every discussion of positive animal findings.
Key Terms and Definitions
- C-terminal fragment
- A peptide segment taken from the carboxyl end of a larger protein.
- Lipolysis
- The biochemical breakdown of stored triglycerides into glycerol and fatty acids; a measured laboratory process, not a synonym for proven human weight loss.
- Fat oxidation
- Use of fatty acids as metabolic fuel, measured in the cited animal experiments through indirect calorimetry.
- Growth hormone receptor
- The receptor activated by intact hGH; one cited study reported that AOD9604 did not bind or activate it in the tested assays.
- Beta-3 adrenergic receptor
- An adrenergic receptor studied in adipose-tissue metabolism and in AOD9604 mouse experiments.
- Phase 2B study
- A mid-stage controlled study intended to examine efficacy and dose-related questions before confirmatory development.
Frequently Asked Questions About AOD9604 Research
What is AOD9604?
AOD9604 is a synthetic, modified C-terminal fragment of human growth hormone. An analytical paper describes it as hGH amino acids 177–191 with an additional N-terminal tyrosine.
Is AOD9604 the same as HGH fragment 176–191?
The names are often used loosely in commerce, but exact identity matters. Published analytical work defines AOD9604 as residues 177–191 plus an added N-terminal tyrosine, while “HGH fragment 176–191” can describe a related sequence without proving it is chemically identical.
How is AOD9604 different from full human growth hormone?
AOD9604 is a short modified fragment rather than the full 191-amino-acid hormone. In preclinical studies it did not bind the hGH receptor or trigger the same receptor-dependent cell-proliferation assay response as intact hGH.
What mechanisms have AOD9604 studies examined?
Rodent studies examined fat oxidation, lipolysis, energy balance, and beta-3 adrenergic receptor expression. Those models do not establish a human mechanism or a clinical outcome.
Did AOD9604 succeed in human obesity trials?
No conclusive efficacy was established. FDA’s 2024 review reports that a 24-week Phase 2B study did not produce the weight-loss result needed to support commercial development, which was then terminated for obesity.
Are AOD9604 trials listed on ClinicalTrials.gov?
FDA reported that its search did not find AOD9604 studies on ClinicalTrials.gov. The agency reconstructed the major trial history from company and regulatory records rather than a registered study entry.
Does AOD9604 have FDA drug approval?
No. FDA states that neither AOD9604 free base nor AOD9604 acetate is a component of an FDA-approved drug.
Does AOD9604 have FDA GRAS status?
Claims about “FDA GRAS approval” should be treated cautiously. FDA’s 2024 compounding review did not identify AOD9604 as an approved drug and evaluated a private GRAS claim as part of the nomination record; GRAS is a food-law concept, not drug approval.
What are the main limits of AOD9604 research?
Much of the mechanistic evidence comes from rodents, the key Phase 2B result was not published as a full peer-reviewed clinical paper, human pharmacokinetic information was limited, and FDA identified unresolved safety concerns for proposed compounded uses.
Is BioPharma AOD9604 5mg intended for human use?
No. BioPharma lists AOD9604 5mg for laboratory and research use only. The vial amount is not a dose, route, administration instruction, treatment recommendation, or clinical protocol.
Sources
- Cox HD, et al. Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. PMID 25208511.
- Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. PMID 11146367.
- Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. PMID 11673763.
- Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism in obese and beta-3-AR knockout mice. PMID 11713213.
- AOD-9604 Metabolic development summary. PMID 15134286.
- FDA. Evaluation of AOD-9604-Related Bulk Drug Substances for the 503A Bulks List. Pharmacy Compounding Advisory Committee briefing document, November 2024.
AOD9604 Research Material at BioPharma
Qualified laboratories can review BioPharma AOD9604 5mg research material and browse the Weight Loss Research catalog. For broader context on evidence and material evaluation, see BioPharma’s research peptides guide and certificate-of-analysis guide. Catalog availability does not imply a protocol, clinical indication, or expected outcome.
Research disclaimer: For research and laboratory use only. Not intended for human or veterinary use. This article does not constitute medical advice. BioPharma does not provide dosing, route, administration, treatment, efficacy, or safety guidance.
